WTX101-201: A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of TWX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older

Project: Research project

Project Details

StatusFinished
Effective start/end date1/21/15 → 1/21/18

Funding

  • Agility Clinical (WTX101-201)
  • Wilson Therapeutics AB (WTX101-201)